Literature DB >> 21136338

[Psychotherapy of borderline personality disorder: similarities and differences in evidence-based disorder-specific treatment approaches].

D Sollberger1, M Walter.   

Abstract

Borderline personality disorder (BPD) is known as a serious psychiatric disorder with high prevalence rates in clinical psychiatric populations. BPD is often very difficult to treat and is linked with conflicts among therapists and treatment teams. Over the last decades, in particular, neurobiological findings and psychotherapeutic research have led to a better understanding and treatment outcomes in BPD. The therapy of choice is psychotherapy. In the following review four efficient disorder-specific treatments for BPS are presented, two of which are cognitive-behaviourally oriented (dialectical behavioural therapy, DBT; scheme-focused therapy, SFT), and the other two are psychodynamically oriented (transference focused psychotherapy, TFP; mentalisation-based treatment, MBT). In this review, the similarities and differences of the methods are elaborated and discussed. After the current considerable progress in disorder-specific treatments for BPS, the development of differential indication criteria for the various treatments could lead to an additional improvement of BPD therapy in the future. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 21136338     DOI: 10.1055/s-0029-1245626

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  2 in total

1.  A relationship between factitious disorder and borderline personality disorder.

Authors:  Dwayne K Gordon; Randy A Sansone
Journal:  Innov Clin Neurosci       Date:  2013-11

2.  A bifactor model of personality organization in adolescence: the validity of a brief screening measure assessing severity and core domains of functioning.

Authors:  M Biberdzic; B F Grenyer; L Normandin; K Ensink; J F Clarkin
Journal:  BMC Psychiatry       Date:  2022-07-08       Impact factor: 4.144

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.